CTNM
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ$14.15
Mkt Cap $528.3M
52w Low $3.35
83.2% of range
52w High $16.33
50d MA $13.48
200d MA $11.53
P/E (TTM)
-6.1x
EV/EBITDA
-3.7x
P/B
1.4x
Debt/Equity
0.0x
ROE
-23.0%
P/FCF
-5.7x
RSI (14)
—
ATR (14)
—
Beta
1.39
50d MA
$13.48
200d MA
$11.53
Avg Volume
280.5K
About
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fi…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.50 | -0.49 | +2.0% | 13.81 | +6.5% | +0.5% | -2.0% | -2.9% | +8.5% | +0.4% | — |
| Oct 30, 2025 | AMC | -0.58 | -0.45 | +22.4% | 10.54 | +0.9% | +4.5% | +1.0% | -1.4% | -0.9% | +4.5% | — |
| Aug 5, 2025 | AMC | -0.56 | -0.62 | -10.7% | 6.00 | +3.0% | +5.5% | +12.2% | +7.8% | +7.2% | +12.5% | — |
| May 14, 2025 | AMC | -0.56 | -0.62 | -10.7% | 3.84 | +0.0% | +2.6% | -8.6% | +13.8% | -0.3% | +0.5% | — |
| Mar 6, 2025 | AMC | -0.44 | -0.56 | -27.3% | 6.44 | -0.6% | +5.1% | +14.9% | +17.5% | +17.4% | +10.9% | — |
| Nov 6, 2024 | AMC | -0.41 | -0.40 | +2.4% | 17.24 | +0.6% | +7.6% | +6.7% | +12.2% | +13.9% | +8.6% | — |
| Aug 13, 2024 | AMC | -0.35 | -0.39 | -11.4% | 16.27 | +0.6% | +6.2% | +14.3% | +5.3% | +14.3% | +8.2% | — |
| May 16, 2024 | AMC | -0.46 | -3.55 | -671.7% | 14.96 | -1.4% | +3.6% | +5.0% | +7.0% | +6.0% | +7.7% | — |
| Dec 31, 2023 | AMC | — | -0.31 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.25 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | Baird | Maintains | Outperform → Outperform | — | $13.81 | $14.71 | +6.5% | +0.5% | -2.0% | -2.9% | +8.5% | +0.4% |
| Jan 8 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $9.56 | $9.09 | -4.9% | -4.1% | -2.6% | -4.1% | +14.0% | +23.0% |
| Nov 24 | Baird | Maintains | Outperform → Outperform | — | $10.95 | $10.87 | -0.7% | -5.4% | -2.2% | -1.7% | +1.1% | +0.4% |
| Nov 21 | RBC Capital | Maintains | Outperform → Outperform | — | $12.22 | $10.97 | -10.2% | -10.4% | -15.2% | -12.4% | -11.9% | -9.4% |
| Aug 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.38 | $7.44 | +0.8% | +9.8% | +26.0% | +20.2% | +36.0% | +34.7% |
| May 19 | Morgan Stanley | Maintains | Overweight → Overweight | — | $3.51 | $3.51 | +0.0% | +24.5% | +9.1% | +10.0% | +11.4% | +1.7% |
| May 15 | RBC Capital | Maintains | Outperform → Outperform | — | $3.84 | $3.84 | +0.0% | +2.6% | -8.6% | +13.8% | -0.3% | +0.5% |
| Mar 7 | Baird | Maintains | Outperform → Outperform | — | $6.44 | $6.40 | -0.6% | +5.1% | +14.9% | +17.5% | +17.4% | +10.9% |
| Jan 9 | RBC Capital | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Nov 7 | RBC Capital | Maintains | Outperform → Outperform | — | $17.24 | $17.34 | +0.6% | +7.6% | +6.7% | +12.2% | +13.9% | +8.6% |
Recent Filings
Data updated apr 25, 2026 3:44am
· Source: massive.com